Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
VXAG-1.1NN by Vaxart for Norovirus Infections: Likelihood of Approval
VXAG-1.1NN is under clinical development by Vaxart and currently in Phase II for Norovirus Infections. According to GlobalData, Phase II...